UPDATED: Aug. 5 at 12:45 ET
CVS Health is rethinking its weight management programs with better patient access and enhanced supports for individuals taking GLP-1s.
The healthcare giant said Wednesday morning that its pharmacies offer all Food and Drug Administration-approved GLP-1s though either insurance or cash-pay options, but it will be working with Eli Lilly to offer a new touchpoint for Zepbound and Foundayo through its app.
By the beginning of the fourth quarter, eligible patients taking either of these medications will be able to access transparent pricing information, including their cash-pay costs, through the app and then secure the GLP-1s for pickup at one of its pharmacies.
"This builds on our existing relationship with Novo to dispense oral and injectable Wegovy, making CVS Pharmacy a convenient, affordable destination for all FDA-approved GLP-1s," CEO David Joyner said on the company's earnings call.
In addition, CVS said that it will implement enhanced pharmacy supports to make it easier for patients who do access these drugs to stick with them, according to the announcement. The company will also add new online visits with MinuteClinic, costing patients $29, where they can be evaluated for GLP-1s, with clinicians prescribing the drugs when appropriate.
Joyner said that its pharmacists are a "key differentiator" in its approach to weight management and support for GLP-1 use. They are a trusted clinician for patients who can assist in managing side effects, answering their questions and supporting adherence.
These services will become especially valuable as the Medicare bridge program, which offers coverage for the drugs for seniors, continues to mature, Joyner said.
The efforts around GLP-1s also fit within the company's broader push to support a simpler patient and consumer experience, he added.
"Our work with GLP-1s is one example of how we can bring our assets together around a consumer need," Joyner said.
PUBLISHED: Aug. 5 at 7:26 a.m. ET
CVS raises guidance, posts $3B profit, $10.6B revenue for Q2
CVS Health is raising its guidance for the year as it blew past Wall Street analysts' expectations in the second quarter.
The company reported just shy of $3 billion in profit for the quarter as well as $106.1 billion in revenue, both of which surpassed analysts' predictions, according to Zacks Investment Research. By comparison, the company posted $1 billion in profit and $98.9 billion in revenue for the prior-year quarter, per its earnings report released Wednesday.
Through the first half of the year, profits were $5.9 billion and revenue was $206.5 billion. Both figures grew significantly from the $2.8 billion in profit and $193.5 billion in revenue reported in the first six months of 2025.
A key bright spot in Q2 was the company's Aetna unit, which has been at the center of margin improvement efforts for several years. Revenues were up by 3.5% in the quarter, reaching $37.5 billion due to growth in its government plans.
That revenue increase was partially offset by the company's decision to exit the Affordable Care Act's exchanges, the company said.
In addition, Aetna's medical loss ratio decreased to 87.4% from 89.9% in the prior-year quarter as the company saw improvements in the performance of its government segment. Total membership was 26 million, on par with the 26.7 million reported in Q2 2025.
Meanwhile, revenues at CVS' health services division—which houses its pharmacy benefit manager, Caremark—were $51.8 billion in the second quarter, up 11.5% from the $46.5 billion reported a year ago.
CVS attributed the growth to pharmacy drug mix and inflation for branded drugs, and said the revenue increases were offset in part by ongoing pricing improvements for clients.
Revenue for CVS' pharmacy and consumer wellness division stayed largely flat, as the company posted $33.8 billion. By comparison, revenues for the pharmacy unit were $33.6 billion in the prior-year quarter.
Pharmacy drug mix and higher volume, bolstered in part by Rite Aid assets that the company acquired last year, both increased revenue, supporting the slim increased, while regulatorily set price reductions on certain drugs, the launch of new generics and pressure on pharmacy reimbursement dragged revenue growth, CVS said.
Due to the performance, the company is raising its guidance from between $7.30 and $7.50 in earnings per share to between $7.90 and $8.10.
In the press release, CEO David Joyner said the improvements reflect the team's commitment to simplifying the healthcare experience.
"As our businesses work together to deliver a technology-powered care engagement experience, we continue to deliver strong performance," he said. "We uniquely enable what our customers want the most: simple, connected and convenient access to affordable, quality healthcare, where, when, and how they want it."